Need for HIV and TB point-of-care diagnostic tests in low-resource settings. For HIV, there is currently, no point-of-care viral load diagnostic is available, and the existing HIV VL tests are expensive and require centralized testing. For TB, market competition is needed to increase competitive pricing, improve decentralized performance and improve multidrug resistance detection.
To fund diagnostics tests across our major disease areas. We drive down costs and drive up accessibility by increasing decentralization of availability to diagnostics.
Develops, manufactures and commercializes patient diagnosis, monitoring, and health management products
Foundation focus: Automated manufacturing lines for three diagnostic tests: HIV viral load, TB detection and TB drug resistance assessment
Low-interest subordinate loan
Date: February 2013
Associated funding: Attendant grant to develop both a TB detection and drug resistance test